DEVELOPMENT OF MULTI-FUNCTIONAL MAGNETIC NANOPARTICLES FOR TARGETED DELIVERY OF ANTICANCER DRUGS

Abstract: 

Conventional cancer chemotherapy is often ineffective. It is also associated with serious side-effects and development of drug resistance. In order to overcome the problems associated with conventional chemotherapy, extensive research is being performed on the development of anticancer drug delivery systems(DDS) which would be able to selectively deliver their drug-load to cancer cells.

The objective of the present proposal is the development of anticancer magnetic DDS (MagDDS) for a safer and more effective cancer chemotherapy compared to current methods. MagDDS will be designed in order to exhibit tumor-targeting and tumor-imaging properties. The more selective drug delivery to the tumor cells will reduce side-effects, while tumor imaging (using MRI) allows simultaneous monitoring of the disease progress. Furthermore, with the application of external alternating magnetic fields, the magnetic nanoparticles will release heat which could act synergistically with the drug action in the necrosis of cancer cells and/or restricting the cancer cells ability to develop drug resistance.

In the context of this project, it is expected to obtain novel magnetic anticancer DDS, characterized by multifunctionality: selectivity (tumor-targeting ability), improved cell penetration ability (carriers expressing cell penetrating peptide), increased anticancer activity (chemotherapy plus hyperthermia), and tumor-imaging ability.

Proof of concept for the effectiveness and safety of the MagDDS will be obtained in animal cancer models. These nanocarriers will represent a significant step toward the development of safe and effective cancer treatment modalities. In addition, new knowledge will be obtained for MagDDS regarding the structure-property interdependence, which will advance current understanding on the key structural characteristics related to their successful application in cancer treatment.

Project info

Acronym:
MAGNANODRUGS
Coordinating Institution:
University of Patras
Scientific Coordinator:
Avgoustakis Konstantinos
Research Team 2 Leader:
Pispas Asterios (Stergios)
Research Team 3 Leader:
Bouropoulos Nikolaos
Research Team 4 Leader:
Papadimitriou Evangelia

Stats

I.D.:
288
Mis:
380212
Duration (months):
36
Budget:
600 000.00
Diavgeia:
ΑΔΑ: Β4169-ΘΘΛ

News